Gendicine
Gendicine is a gene therapy medication used to treat patients with head and neck squamous cell carcinoma linked to mutations in the TP53 gene. It consists of recombinant adenovirus engineered to code for p53 protein (rAd-p53) and is manufactured by Shenzhen SiBiono GeneTech.
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
Gendicine was the first gene therapy product to obtain regulatory approval for clinical use in humans after Chinese State Food and Drug Administration approved it in 2003.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.